Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced Nsclc

NCT01858389 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01858389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01858389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced Nsclc
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
September 30, 2015
Enrollment
41 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer